|
|
Vaccine Detail
|
RVΔP-MERS/S1 |
| Vaccine Information |
- Vaccine Name: RVΔP-MERS/S1
- Target Pathogen: MERS-CoV
- Target Disease: Middle East Respiratory Syndrome (MERS)
- Type: Recombinant vector vaccine
- Status: Licensed
- Host Species for Licensed Use: Baboon
- Antigen: S1 subunit of S protein (Kato et al., 2019)
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: Recombinant RVΔP that expresses S1 fused with transmembrane and cytoplasmic domains together with 14 amino acids from the ectodomains of the RV-glycoprotein (RV-G)(Kato et al., 2019)
|
| Host Response |
|
Mouse Response
- Host Strain: BALB/c (Kato et al., 2019)
- Host age: 3 weeks old (Kato et al., 2019)
- Host gender: Female (Kato et al., 2019)
- Vaccination Protocol: All mice were inoculated intraperitoneally with 100 μL of each virus solution containing 107 FFU/mL or PBS, with the day on which mice were inoculated with viruses defined as day 0. (Kato et al., 2019)
- Immune Response: increased neutralizing antibody titer for MERS-CoV and rabies virus (Kato et al., 2019)
- Description: Safety profile indicated no deaths when inoculated intracerebrally for three weeks with 107 FFU/mL of RVΔP-MERS/S1.
|
| References |
Kato et al., 2019: Kato H, Takayama-Ito M, Iizuka-Shiota I, Fukushi S, Posadas-Herrera G, Horiya M, Satoh M, Yoshikawa T, Yamada S, Harada S, Fujii H, Shibamura M, Inagaki T, Morimoto K, Saijo M, Lim CK. Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice. PloS one. 2019; 14(10); e0223684. [PubMed: 31589656].
|
|
